Cargando…
PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
Autores principales: | Sucha, S., Sorf, A., Svoren, M., Vagiannis, D., Ahmed, F., Visek, B., Ceckova, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429552/ http://dx.doi.org/10.1097/01.HS9.0000850012.85946.26 |
Ejemplares similares
-
PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
por: Brysting, Josephine, et al.
Publicado: (2023) -
Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
por: Sorf, Ales, et al.
Publicado: (2020) -
PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022) -
PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
por: Reinhardt, Dirk, et al.
Publicado: (2023) -
PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)